53 completed, 4 active not recruiting, 3 terminated, 1 recruiting. 61 Phase 1, 6 Phase 2.
By phase and status
Follow Eisai Co., Ltd.: new trials by email
Trials (filtered) newest first · largest first
All 61 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants Dotinurad - Healthy Volunteers Phase 1 Completed 26 2022-07-01 2023-09-14 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants E6742, Placebo - Lupus Erythematosus, Systemic Phase 1 / Phase 2 Completed 26 2022-04-14 2023-09-29 A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers Aducanumab - Healthy Volunteers Phase 1 Completed 30 2021-06-30 2023-04-13 A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants E6742, Placebo - Healthy Volunteers Phase 1 Completed 24 2020-12-28 2021-07-20 A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants E8001, Placebo - Healthy Volunteers Phase 1 Completed 36 2020-10-28 2023-09-25 A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants Lemborexant - Healthy Volunteer Phase 1 Completed 26 2020-10-26 2021-07-19 A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants E7090, Rabeprazole 20 mg, Rifampin 600 mg - Healthy Participants Phase 1 Completed 42 2020-10-16 2021-11-01 A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms Phase 1 Completed 51 2020-10-09 2026-07-17 Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer H3B-6545, Antihistamine - Breast Neoplasms Phase 1 Completed 33 2020-09-30 2025-10-23 Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants Tasurgratinib - Hepatic Impairment Phase 1 Recruiting 18 2020-02-27 2026-09-17 A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor E7389-LF, Nivolumab - Solid Neoplasms Phase 1 / Phase 2 Active not recruiting 125 2019-09-05 2026-10-13 A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants E0302 SR1, E0302 SR3, E0302 SR2 - Healthy Subjects Phase 1 Completed 24 2019-04-13 2019-12-24 A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) E7386 - Solid Neoplasms, Colorectal Neoplasms Phase 1 Active not recruiting 70 2019-03-05 2026-02-27 Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor lenvatinib - Solid Tumor Phase 1 Completed 12 2018-08-06 2021-09-28 Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects Perampanel - Healthy Subjects Phase 1 Completed 44 2018-03-20 2018-08-28 A Study of E7130 in Participants With Solid Tumors E7130 - Solid Tumors Phase 1 Terminated 62 2018-02-05 2026-10-23 A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma Lenvatinib, Nivolumab - Carcinoma, Hepatocellular Phase 1 Completed 30 2018-01-16 2024-06-20 Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects E2082, Placebo - Healthy Participants Phase 1 Terminated 118 2017-12-21 2021-06-30 Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects Perampanel - Healthy Participants Phase 1 Completed 24 2017-12-18 2018-10-29 Study of E7389 Liposomal Formulation in Participants With Solid Tumor E7389-LF - Solid Tumor Phase 1 Active not recruiting 140 2017-08-18 2026-08-27
Showing 20 of 61. Sign in to see all of them.
Conditions studied Neoplasms (10) · Breast Neoplasms (4) · Carcinoma, Hepatocellular (4) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Gastrointestinal Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Acrocephalosyndactylia (1) · Adrenocortical Carcinoma (1) · Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Carcinoma, Renal Cell (1) · Cognitive Dysfunction (1)
Interventions lenvatinib (10) · Donepezil (3) · Rabeprazole (3) · perampanel (3) · quetmolimab (3) · N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2) · Nivolumab (2) · eribulin (2) · pembrolizumab (2) · 2-(4-(2,2-dimethyl-1,3-dioxan-5-yl)methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl-1H-benzimidazole (1) · Carboplatin (1) · E-7386 (1) · Eszopiclone (1) · Everolimus (1) · Fulvestrant (1)
Countries Japan (48) · China (5) · United States (4) · South Korea (2) · France (1) · Italy (1) · New Zealand (1) · Russia (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Top investigators Hidetaka Hiramatsu (3) · Chifumi Kitamura (2) · Hiroki Shimizu (2) · Kai Shibata (2) · Tadashi Nakanishi (2) · Fuminori Ohba (1) · Hiroshi Obaishi (1) · Kenya Nakai (1) · Kiyoshi Oketani (1) · Mark Yen (1) · Ryo Nakajima (1) · Soo Chin Lee (1) · Takashi Sawada (1)
Results publications PMID 21887501 , PMID 23860537 , PMID 25242374 , PMID 25380636 , PMID 25502863 , PMID 27704266 , PMID 28681650 , PMID 29363235 , PMID 30623276 , PMID 32716739 , PMID 33474967 , PMID 35180771 , PMID 35500404 , PMID 35642432 , PMID 35674480 , PMID 35749284 , PMID 36289094 , PMID 36746851 , PMID 37080942 , PMID 38295160 , PMID 39087871 , PMID 39289029 , PMID 39516370 , PMID 41111126 , PMID 42203677 , PMID 42754887
NIH funding 2015 (1) , 2018 (1)